Head-to-head evidence
Vigabatrin (Sabril) vs Vigabatrin (Vigafyde)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA transaminase (GABA-T) · full Epilepsy pipeline
Vigabatrin (Sabril)
Marketed by Lundbeck LLC and partners
NCT02849457 · Phase 2 · completed
The study enrolled 84 infants, with 56 entering the randomized comparison of early vigabatrin versus matching placebo/delayed vigabatrin; participants, caregivers, and investigators were blinded. The primary clinical-function endpoint, the 24-month Bayley cognitive score, was not met: the adjusted comparison was not statistically significant (p=0.8681), so the results provide well-controlled but unclear evidence of benefit.
Vigabatrin (Vigafyde)
Marketed by Upsher-Smith Laboratories, LLC
NCT04772547 · Phase 2 · completed
This is a single-arm, open-label pilot study of 6 patients, without randomization, a control group, or blinded assessment. Primary endpoints were pharmacokinetic absorption and feasibility targets: detectable vigabatrin at 3 hours (6/6) and drug delivery within 48 hours (6/6) were achieved, but ≥80% completion of taurine draws was not (1/2 at 168h) and visual-field testing could not be done because all 6 patients died in-hospital. With no comparator and a very small sample, the results are descriptive only.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Vigabatrin (Sabril)'s landscape · Vigabatrin (Vigafyde)'s landscape